Clinical Trials Browser

Phase 1/2 × rilotumumab × Thoracic × Clear all

NCT00791154 2024-08-23

SCLC

Phase 1/2 Terminated

213 enrolled 16 charts

Lung Neoplasms, Pleural Effusion, Malignant, Small Cell Lung Carcinoma

NCT01233687 2017-06-22

AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer

Phase 1/2 Completed

49 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Recurrence